The Impact of Hormone Therapy on Lower Urinary Tract Symptoms, Sexual Function and Psychosomatic Disorder
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Menopausal syndromes includes somatic symptom, psychosomatic symptoms, sexual dysfunction and
even urinary symptoms. Hormone therapy (HT) is widely used for controlling menopausal
symptoms. Common HT for menopausal syndrome with intact uterus includes tibolone, estradiol
valerate (E2V) 1mg & medroxyprogesterone acetate (MPA) 2.5 mg, and conjugated equine
estrogens & MPA.
However, only a few literatures mentioned about the therapeutic effect of tibolone, but lack
of comparison research about their therapeutic effect on somatic symptoms, psychosomatic
symptoms, sexual dysfunction and even urinary symptoms. The knowledge of the above
therapeutic effects should be important for choosing a suitable medication. Therefore, the
aim of this study is to assess the therapeutic effect on somatic symptoms, psychosomatic
symptoms, sexual dysfunction and even urinary symptoms between tibolone and E2V/MPA.